FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical chemistry, specifically to use of a compound of formula (I), where A is OH-group or OCH3-group; R is a hydrogen atom, CH3-group or cyclopropylmethyl group; X is an oxygen atom, Y is an oxygen atom or a CH2-group, Z is a hydrogen atom or OH-group.
EFFECT: technical result: novel use of compound of formula (I) for treating or preventing autoimmune hepatitis.
6 cl, 4 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF MALIGNANT TUMOUR WITH NALTREXONE | 2014 |
|
RU2686325C2 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
| OPIOID RECEPTOR ANTAGONIST (NALTREXONE) APPLICABLE IN THERAPY OF HERPES ZOSTER | 2011 |
|
RU2561871C2 |
| METHOD OF COMPLEX PATHOGENETIC THERAPY OF ACUTE FORMS OF VIRAL HEPATITIS B AND MIXED HEPATITES (B+C, B+D, B+C+D) | 2010 |
|
RU2440128C1 |
| MULTICOMPONENT VACCINE FOR IMMUNOPROPHYLAXIS AND IMMUNOTHERAPY OF DISEASES CAUSED BY OPPORTUNISTIC PATHOGENS | 2022 |
|
RU2786222C1 |
| PROPHYLAXIS AND TREATMENT OF INFECTIOUS AND OTHER DISEASES BY USING COMPOUNDS BASED ON MONO- N DISACCHARIDES | 2001 |
|
RU2289410C2 |
| INTRODUCTION OF ERYTHORANE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR ORTHOMYXOVIRAL INFECTIONS TREATMENT | 2013 |
|
RU2636622C2 |
| PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | 2012 |
|
RU2789326C1 |
| METHOD FOR EVALUATING AUTOIMMUNITY TO HUMAN HEPATIC ANTIGEN | 2005 |
|
RU2293335C1 |
| PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | 2012 |
|
RU2678561C9 |
